Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Director Leonard Sank purchased 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The shares were bought at an average price of $3.47 per share, with a total value of $69,400.00. Following the acquisition, the director now directly owns 315,482 shares of the company’s stock, valued at approximately $1,094,722.54. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Leonard Sank also recently made the following trade(s):
- On Thursday, July 18th, Leonard Sank purchased 4,497 shares of Oramed Pharmaceuticals stock. The shares were bought at an average price of $3.86 per share, with a total value of $17,358.42.
- On Thursday, July 11th, Leonard Sank purchased 1,320 shares of Oramed Pharmaceuticals stock. The shares were bought at an average price of $3.22 per share, with a total value of $4,250.40.
Shares of Oramed Pharmaceuticals stock opened at $3.87 on Friday. The stock’s fifty day moving average is $3.42. Oramed Pharmaceuticals, Inc. has a 12-month low of $2.78 and a 12-month high of $5.89. The company has a market capitalization of $68.83 million, a P/E ratio of -4.50 and a beta of 1.37.
A hedge fund recently raised its stake in Oramed Pharmaceuticals stock. BlackRock Inc. raised its holdings in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 69,343 shares of the biotechnology company’s stock after acquiring an additional 40,114 shares during the period. BlackRock Inc. owned approximately 0.40% of Oramed Pharmaceuticals worth $208,000 at the end of the most recent reporting period. 6.18% of the stock is currently owned by hedge funds and other institutional investors.
Separately, HC Wainwright reiterated a “buy” rating on shares of Oramed Pharmaceuticals in a report on Wednesday, June 19th.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Featured Story: How do taxes affect a CDs total return?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.